Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients

Colorectal cancer, fourth leading form of cancer worldwide and is increasing in alarming rate in the developing countries. Treating colorectal cancer has become a big challenge worldwide and several antibody therapies such as bevacizumab, panitumumab and cetuximab are being used with limited success...

Descripción completa

Detalles Bibliográficos
Autores principales: Pathak, Surajit, S, Sushmitha, Banerjee, Antara, Marotta, Francesco, Gopinath, Madhumala, Murugesan, Ramachandran, Zhang, Hong, B, Bhavani, Girigoswami, Agnishwar, Sollano, Jose, Sun, Xiao-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800940/
https://www.ncbi.nlm.nih.gov/pubmed/29484148
http://dx.doi.org/10.18632/oncotarget.22471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800940/
https://www.ncbi.nlm.nih.gov/pubmed/29484148
http://dx.doi.org/10.18632/oncotarget.22471

Ejemplares similares